Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia

Current Medical Research and Opinion

Volumn 27, Issue 5, 2011, Pages 939-950

  Armstrong, Edward P ^a,b   Malone, Daniel C ^a,b   McCarberg, Bill ^c   Panarites, Christopher J ^d   Pham, Sissi V ^e  

^a UNIVERSITY OF ARIZONA   (United States)

^b Strategic Therapeutics LLC   (United States)

^c Chronic Pain Management Program   (United States)

^d NeurogesX Inc   (United States)

^e Sissi Pham Consulting Inc   (United States)

Author keywords

Duloxetine; Gabapentin; Postherpetic neuralgia; Pregabalin; Topical capsaicin patch; Topical lidocaine

Indexed keywords

CAPSAICIN; DULOXETINE; GABAPENTIN; LIDOCAINE; NORTRIPTYLINE; OXYCODONE; PREGABALIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; MANAGED CARE ORGANIZATION; POSTHERPETIC NEURALGIA; QUALITY ADJUSTED LIFE YEAR; SYSTEMATIC REVIEW;

ADMINISTRATION, TOPICAL; AMINES; ANESTHETICS, LOCAL; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CAPSAICIN; CLINICAL TRIALS AS TOPIC; COSTS AND COST ANALYSIS; CYCLOHEXANECARBOXYLIC ACIDS; DOPAMINE UPTAKE INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LIDOCAINE; MALE; MARKOV CHAINS; NEURALGIA, POSTHERPETIC; QUALITY OF LIFE; SENSORY SYSTEM AGENTS; THIOPHENES; TRANSDERMAL PATCH;

EID: 79954507290     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.562885     Document Type: Article

References (79)

1. Young L. Post-herpetic neuralgia: a review of advances in treatment and prevention. J Drugs Dermatol 2006;5:938-41.
2. Johnson RW, Wasner G, Saddier P, et al. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurotherapeutics 2007; 7:1581-95. (Pubitemid 350106836)
3. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18: 350-4. (Pubitemid 35291575)
4. Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ 2003;326: 748-50. (Pubitemid 36408042)
5. Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009;137:38-47.
6. Rodriguez MJ, Garcia AJ. A registry of the aetiology and costs of neuropathic pain in pain clinics. Results of the Registry of Etiologies and Costs (REC) in neuropathic pain disorders study. Clin Drug Invest 2007;27:771-82. (Pubitemid 47529293)
7. Di Legami V, Gianino MM, Atti MCDA, et al. Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. Vaccine 2007;25:7598-604. (Pubitemid 47503489)
8. McCarberg B, Billington R. Consequences of neuropathic pain: quality of life issues and associated costs. Am J Managed Care 2006;12(Suppl):S263-8. (Pubitemid 43993104)
9. Oster G, Harding G, Dukes E, et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005;6:356-63. (Pubitemid 40804340)
10. Besson M, Piguet V, Dayer P, et al. New approaches to the pharmacotherapy of neuropathic pain. Expert Rev Clin Pharmacol 2008;1:683-93.
11. Zin CS, Nissen LM, Smith MT, et al. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs 2008;22:417-42.
12. Tyring SK. Management of herpes zoster and postherpetic neuralgia. J Am Acad Dermatol 2007;57:S136-42. (Pubitemid 350087358)
13. Gidal B, Billington R. New and emerging treatment options for neuropathic pain. Am J Managed Care 2006;12:S269-78. (Pubitemid 43993105)
14. Deshpande MA, Holden RR, Gilron I. The impact of therapy on quality of life and mood in neuropathic pain: what is the effect of pain reduction? Pain Med 2006;102:1473-9.
15. McDermott AM, Toelle TR, Rowbotham DJ, et al. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 2006;10:127-35. (Pubitemid 41727763)
16. Gore M, Sadosky A, Tai KS, et al. A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usualcare settings. Clin Ther 2007;29:1655-70. (Pubitemid 47500130)
17. Dworkin RH, White R, O'Conner AB, et al. Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. J Am Geriatr Soc 2007;55:1168-75. (Pubitemid 47106670)
18. Finnerup NB, Otto M, Jensen TS, et al. An evidence-based algorithm for the treatment of neuropathic pain. Medscape Gen Med 2007;9:36.
19. Hempenstall K, Nurmikko TJ, Johnson RW, et al. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005; 2(7):e164.
20. Dworkin RH, O'Conner AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237-51. (Pubitemid 350051570)
21. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289-305. (Pubitemid 41752987)
22. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13:1153-69. (Pubitemid 44581463)
23. Katz J, Finnerup NB, Dworkin RH. Clinical trial outcome in neuropathic pain. Relationship to study characteristics. Neurology 2008;70:263-72. (Pubitemid 351156805)
24. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003;163:2716-24. (Pubitemid 37517412)
25. Farrer JT, Young JP, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58.
26. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19. (Pubitemid 40038441)
27. Goldstein DJ, Detke MJ, Lee TC, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-18. (Pubitemid 40828506)
28. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-56. (Pubitemid 41727332)
29. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006; 67:1411-20. (Pubitemid 44632065)
30. Rice ASC, Maton S, Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001;94:215-24. (Pubitemid 33016615)
31. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003;106:151-8. (Pubitemid 37329625)
32. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia. A randomized, placebo-controlled trial. Neurology 2002;59:1015-21.
33. Backonja M, Wallace M, Blonsky E, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind study. Lancet Neurol 2008;7:1106-12.
34. Irving GA, Backonja MM, Dunteman E, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med 2011; 12:99-109.
35. Watson CPN, Vernich L, Chipman M, et al. Nortriptyline versus amitriptyline in postherpetic neuralgia. A randomized trial. Neurology 1998;51:1166-71. (Pubitemid 28473420)
36. Kishore-Kumar R, Max M, Schafer SC, et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther 1990;47:305-12. (Pubitemid 20115016)
37. Watson CP, Evans RJ, Reed K, et al. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982;32:671-3. (Pubitemid 12119035)
38. Max MB, Schafer SC, Culnane M, et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988;38:1427-32.
39. Graff-Radford SB, Shaw LR, Naliboff BN. Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia. Clin J Pain 2000;16:188-92.
40. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia. A randomized controlled trial. JAMA 1998; 280:1837-42. (Pubitemid 28544424)
41. Dworkin RH, Corbin AE, Young JP, et al. Pregabalin for the treatment of postherpetic neuralgia. A randomized, placebo-controlled trial. Neurology 2003;60:1274-83. (Pubitemid 36460982)
42. Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004; 109:26-35. (Pubitemid 38479767)
43. van Seventer R, Feister HA, Young JP, et al. Efficacy and tolerability of twicedaily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 2006; 22:375-84. (Pubitemid 44296762)
44. Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain1999;80:533-8. (Pubitemid 29182702)
45. Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: doubleblind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996;65:39-44. (Pubitemid 26227686)
46. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol 1995;37:246-53.
47. Wasserman Y. 2009 Physicians' Fee Reference Comprehensive Fee Report (26th edn). Milwaukee: Yale Wasserman, D.M.D. Medical Publishers, Ltd., 2009.
48. US Food and Drug Administration. FDA Drug Approval Package for Qutenza (capsaicin) 8% patch, Application No.: 022395, Tables 5. 3.5 & 5. 3.18. Available at http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/ 022395s000Medr.pdf [Last accessed October 4, 2010].
49. Centers for Medicare and Medicaid Services. ASP Drug Pricing Files October 2010 Update. Available at http://www.cms.gov/McrPartBDrugAvgSalesPrice/ 01a19-2010aspfiles.asp#TopOfPage [Last accessed October 4, 2010].
50. Sullivan PW, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004;18:911-32. (Pubitemid 39612019)
51. Lieu TA, Ortega-Sanchez I, Ray T, et al. Community and patient values for preventing herpes zoster. Pharmacoeconomics 2008;26:235-49. (Pubitemid 351278369)
52. Sarasin FP, Eckman MH. Management and prevention of thromboembolic events in patients with cancer-related hypercoagulable states: a risky business. J Gen Intern Med 1993;8:476-86. (Pubitemid 23277846)
53. Revicki DA, Wood M. Patient-assigned health state utilities for depressionrelated outcomes: differences by depression severity and antidepressant medications. J Affective Disord 1998;48:25-36. (Pubitemid 28078968)
54. Ebell MH, Warbasse L, Brenner C. Evaluation of the dyspeptic patient: a costutility study. J Fam Pract 1997;44:545-55. (Pubitemid 27255346)
55. Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 2000;92:1731-9.
56. Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol 2003;43:111-17. (Pubitemid 36125935)
57. Lyrica (pregabalin) package insert. New York (NY): Pfizer, June 2007.
58. Neurontin (gabapentin) package insert. New York (NY): Pfizer, January 2007.
59. Cymbalta (duloxetine) package insert. Indianapolis (IN): Eli Lilly and Company, December 2007.
60. Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004;7:518-28. (Pubitemid 39390832)
61. Rascati KL. The $64,000 question-what is a quality-adjusted life-year worth? Clin Ther 2006;28:1042-3. (Pubitemid 44380317)
62. National Institute for Health and Clinical Excellence. http://www.nice.org.uk/(Accessed January 10, 2010).
63. Backonja M, Malan TP, Vanhove GF, et al. A high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med 2010;11:600-8.
64. Simpson DM, Gazda S, Brown S, et al. Long-term safety of NGX-4010, a high-concentration capsaicin patch, for the treatment of neuropathic pain in patients with painful HIV-distal sensory polyneuropathy (HIV-DSP) or postherpetic neuralgia (PHN). J Pain Symptom Manage 2010;39:1053-64.
65. Smith KJ, Roberts MS. Sequential medication strategies for postherpetic neuralgia: a cost-effectiveness analysis. J Pain 2007;8:396-404. (Pubitemid 46678930)
66. O'Conner AB, Noyes K, Holloway RG. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. J Am Geriatr Soc 2007;55:1176-84. (Pubitemid 47106676)
67. Kirson NY, Ivanova JI, Birnbaum HG, et al. Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%. J Med Econ 2010;13:472-81.
68. Tarride JE. Gordon A, Vera-Llonch M, et al. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clin Ther 2006;28:1922-34. (Pubitemid 46043510)
69. Cepeda MS, Farrar JT. Economic evaluation of oral treatments for neuropathic pain. J Pain 2006;7:119-28. (Pubitemid 43197620)
70. Rodriguez MJ, Diaz S, Vera-Llonch M, et al. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin 2007; 23:2585-96. (Pubitemid 350033461)
71. Perez C, Navarro A, Saldana MT, et al. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study. Clin Ther 2010;32:1357-70.
72. Dakin H, Nuijten M, Liedgens H, et al. Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for Postherpetic neuralgia in the United Kingdom. Clin Ther 2007;29:1491-507. (Pubitemid 47348109)
73. Liedgens H, Hertel N, Gabriel A, et al. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia. A German perspective. Clin Drug Invest 2008;28:583-601.
74. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005;6:253-60. (Pubitemid 40488803)
75. van Seventer R, Feister HA, Young JP, et al. Efficacy and tolerability of twicedaily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 2006; 22:375-84. (Pubitemid 44296762)
76. Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy. A randomized controlled trial. Neurology 2004; 63:2104-10. (Pubitemid 39636259)
77. Dallocchio C, Buffa C, Mazzarello P, et al. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage 2000;20:280-5.
78. Moore RA, Eccleston C, Derry S, et al. "Evidence" in chronic pain-establishing best practice in the reporting of systematic reviews. Pain 2010; 150:386-9.
79. O'Connor AB. Neuropathic pain. Quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics 2009;27:95-112